report publish origin email
thesi continu argu gilead offer investor opportun
buy high-risk high-reward biotech pipelin valuat
fulli discount rapid eros hepat hcv franchis
buy thesi remain unchang follow result await
public fulli updat forecast
gilead manag re-affirmed guidanc alongsid result
sale estim better gross margin/low spend result
ep estim fig reduc estim
move hcv forecast middl guidanc
rang reflect rapid volum share eros outsid us
season us wholesal de-stock us hiv busi move
exacerb addit de-stock follow launch biktarvi
de-stock versu de-stock versu
addit de-stock account revenu miss versu
us hiv wholesal destock quantifi time result
lead uncertainti surround gilead core growth franchis
precipit forecast downgrad perform
consensu sale ep respect hiv perform
light expect hcv follow result consensu
downgrad sale ep expect respect
import note inform cover standard regulatori disclosur
print publish research display www redburntoday com
redburn europ limit authoris regul financi conduct author
gilead manag continu guid hcv sale declin
group sale reduc risk profil base busi allow
gilead return growth gilead continu maximis hcv
opportun challeng competit environ manag expect hcv
net price treatment durat market share stabilis
hcv expect predict moder declin franchis
thereaft sign stabilis us fig whilst europ
impact abbvi maviret volum matur outsid franc fig
fig us hcv total prescript share sign stabilis emerg week
fig gilead hcv volum share eu top five
fallen
fig maviret volum share eu top five matur
import note inform cover standard regulatori disclosur
print publish research display www redburntoday com
redburn europ limit authoris regul financi conduct author
argu hcv revenu adjust way investor focu
shift underappreci hiv franchis includ limit
biktarvi pipelin includ cellular therapi platform
opportun augment long-term growth outlook
biktarvi launch follow trajectori set genvoya fig
arguabl straightforward switch stribild strip
genericis viread prescript written hbv gilead
state underli prescript growth us hiv franchis
manag state biktarvi prescript date
come switch switch come dolutegravir-bas
regimen fig import note absolut dolutegravir new-to-brand
prescript nbrx prescript continu grow yoy data avail request
fig us biktarvi launch line genvoya total
argu combin pivot proof-of-concept pipelin data could begin
deliv upsid fair valu upcom pipelin data-point
includ phase data filgotinib rheumatoid arthriti phase
data filgotinib psoriat arthriti phase data selonsertib
nash phase data andexaliximab combin opdivo
gastric cancer earli data car-t asset anti-bcma
clear us gilead remain focus oper financi effici
manag guid modest declin gross margin
despit loss high-margin hcv revenu fig us
corpor tax reform still expect lower group tax rate
increas financi flexibl cash expect repatri
repatri cash allow invest pipelin
 a/partnership opportun debt reduct
import note inform cover standard regulatori disclosur
